Founder Investment: Ritesh Agarwal invested Rs 830 crore in the company’s latest funding round through the Singapore-based entity Patient Capital.
Funding Breakdown: Includes Rs 416.85 crore from Incred Wealth in July 2024 and Rs 1,047 crore approved by shareholders on August 8 in an extraordinary general meeting (EGM).
Leading Investors: InCred Wealth invested Rs 76 crore in addition to Rs 416.85 crore previously, while J&A Partners, the Mankind Pharma family office, invested Rs 120 crore, and ASK contributed Rs 14 crore.
IPO Plans: The Sources confirmed that it will proceed with the IPO only after achieving several profitable quarters, which it anticipates will occur.
Founder’s Ownership: Ritesh Agarwal's stake will increase from 29.97% to 32.57% following the Series G funding round dilution.
